Article

ATR and PKMYT1 inhibition re-sensitize a subset of TNBC patient-derived models to carboplatin inducing mitotic catastrophe

2025-01-10

Abstract excerpt

<h4>ABSTRACT</h4> Triple negative breast cancer (TNBC) is associated with poor prognosis and is mainly treated with chemotherapy-based regimens, often including carboplatin. Resistance to carboplatin is a common clinical issue that is either initially present or develops with treatment. Overcoming this resistance is a significant clinical challenge, which highlights the need for novel therapeutic strategies. We u...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3f1334c1-6a26-5b35-a51b-acae86144a2c
DOI: 10.1101/2025.01.07.629892

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

ATR and PKMYT1 inhibition re-sensitize a subset of TNBC patient-derived models to carboplatin inducing mitotic catastropheDOI 10.1101/2025.01.07.629892Read

Myt1 overexpression mediates resistance to cell cycle and DNA damage checkpoint kinase inhibitorsSemantic proximity Read

Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising TargetsSemantic proximity Read

DNA damage response inhibitors: An avenue for TNBC treatment.Semantic proximity Read

Cancer Vulnerabilities Through Targeting the ATR/Chk1 and ATM/Chk2 Axes in the Context of DNA DamageSemantic proximity Read

Identifying Novel Therapeutic Targets for Overcoming TNBC Chemo Resistance Through Comprehensive CRISPR-Cas9 Genome ScreeningSemantic proximity Read

Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecanSemantic proximity Read

Chromatin signalling pathways and FANCE amplification affect ATR inhibitor sensitivity in metastatic breast cancerSemantic proximity Read

Efficacy and Mechanism of the Combination of PARP and CDK4/6 Inhibitors in the Treatment of Triple-negative Breast CancerSemantic proximity Read

Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapySemantic proximity Read

Carboplatin: molecular mechanisms of action associated with chemoresistanceSemantic proximity Read

Mitotic kinases are emerging therapeutic targets against metastatic breast cancerSemantic proximity Read